Today: 29 April 2026
Lynas Rare Earths share price jumps nearly 8% on ASX as results near and export curbs bite
25 February 2026
2 mins read

Lynas Rare Earths share price jumps nearly 8% on ASX as results near and export curbs bite

Sydney, Feb 25, 2026, 17:57 (AEDT) — Trading wrapped up after the bell.

  • Lynas Rare Earths (ASX:LYC) jumped 7.9% to finish at A$17.03.
  • Fresh export restrictions from China on magnet metals kept rare earth supply jitters alive.
  • Thursday’s half-year results have investors watching for any clues on costs, pricing, and sales volumes.

Lynas Rare Earths Ltd (LYC.AX) surged 7.9% to A$17.03 on Wednesday, hitting as high as A$17.09 during the session, with 7.66 million shares changing hands. The stock closed at A$15.78 the previous day, according to data.

This puts the rare earths producer on track for an important milestone. Lynas plans to release half-year results for the period ended Dec. 31, 2025 this Thursday. CEO Amanda Lacaze is scheduled to lead an analyst and shareholder briefing at 11 a.m. in Sydney.

So why’s this coming up now? Beijing’s been clamping down on strategic minerals, and rare earths tend to swing at any sign of policy tension. On Tuesday, China’s commerce ministry announced it’s blocking exports of dual-use goods—those with both civilian and military applications—to 20 Japanese organizations. The upshot: these firms lose access to tightly controlled rare earth elements like dysprosium, yttrium, and samarium.

Prices aren’t sitting still, particularly beyond China’s borders. Dysprosium fetched roughly $1,000 per kilogram, and terbium’s price hovered near $4,500/kg. Neodymium-praseodymium (NdPr), crucial for magnets, held above the Pentagon’s $110/kg support threshold linked to its agreement with MP Materials, Investors Business Daily said.

The S&P/ASX 200 edged 0.9% higher on Wednesday, paced by strength in materials.

Thursday’s focus for Lynas shareholders isn’t really the geopolitical noise—it’s the hard numbers that count. They’ll be zeroing in on realised prices, what it costs per unit, and how much cash the business is throwing off. Any fresh hints on demand trends from magnet supply chains—especially those trying to loosen ties with China—will get attention, too.

The timing on the half-year print isn’t great. Rising commodity prices might give margins a lift, but they also draw attention to how well the company’s running things. If output, maintenance, or spending slip even a bit, that macro narrative can unravel fast.

There’s risk on the flip side as well. Rare earth prices have a habit of rebounding once policy uncertainty eases or buyers pause to work through existing inventory. If prices drop quickly, that could challenge the upbeat expectations already priced in from the latest surge. The stock remains at the mercy of shifting policy out of China, and there’s still the question of whether alternative supply chains can move past talk and actually supply real material.

Lynas has pushed for pricing that makes investment worthwhile. “We need those customers to buy our product at prices that properly reflect the cost of doing business,” CEO Lacaze said back in January following a quarterly update. Reuters

The half-year numbers land Thursday, followed by an 11 a.m. briefing. Traders are set to parse every word on pricing, costs, and production—plus any hints on whether the latest export curbs are feeding stronger demand abroad, beyond China’s borders.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:56 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Singapore stock market today: STI dips near 5,000 as Genting slides and earnings hit SGX
Previous Story

Singapore stock market today: STI dips near 5,000 as Genting slides and earnings hit SGX

Singapore Airlines Q3 profit dives 69% despite record revenue as Air India losses weigh
Next Story

Singapore Airlines Q3 profit dives 69% despite record revenue as Air India losses weigh

Go toTop